Genmab A/S products

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.1 Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A subcutaneous formulation of daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) has been approved by the U.S. FDA for certain multiple myeloma indications.

Ofatumumab is a human monoclonal antibody which targets an epitope in the CD20 molecule encompassing parts of the small and large extracellular loops.

Tisotumab Vedotin is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis.¹ It is composed of Genmab’s human monoclonal antibody (mAb) that binds to TF and Seagen’s ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE).¹ TF is a transmembrane protein that is the main physiological initiator of coagulation and is involved in angiogenesis, cell adhesion, motility, and cell survival.^2,3 The presence of TF is associated with poor prognosis.

DuoBody PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed by Genmab under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. DuoBody®-PD-L1x4-1BB is designed to elicit an anti-tumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB stimulation, using inert DuoBody IgG1 antibody format.

DuoBody-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent T-cell activation, using an inert DuoBody® format.

GEN3014 (HexaBody^®-CD38) is a novel human CD38 monoclonal antibody incorporating Genmab’s HexaBody^® technology. In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen Biotech Inc. to develop and commercialize HexaBody^®-CD38. In preclinical models of hematological malignancies, HexaBody^®-CD38 demonstrated enhanced complement-dependent cytotoxicity and potent anti-tumor activity^.

DuoBody-CD3xB7H4 (GEN1047) is a proprietary bispecific antibody created using Genmab’s DuoBody® technology. B7H4 is an immune checkpoint protein expressed on malignant cells in various solid cancers including breast, ovarian and lung cancer. In preclinical studies, DuoBody-CD3xB7H4 was shown to induce T-cell mediated cytotoxicity of B7H4-positive tumor cells.

Amivantamab is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform. The two antibody libraries used to produce amivantamab were both generated by Genmab. The antibody pair used to create Amivantamab was selected in collaboration between Genmab and Janssen. Subsequent development work was carried out by Janssen.